omniture

WuXi PharmaTech Appoints Deepak Hegde as VP of Formulation

2007-07-24 20:53 4142

SHANGHAI, China, July 24 /Xinhua-PRNewswire/ -- WuXi PharmaTech, China’s leading supplier of pharmaceutical R&D outsourcing services announced today the appointment of Dr. Deepak Hegde as Vice President of Formulation Development Services.

(Logo: http://www.prnasia.com/sa/200611271812.jpg )

Before joining WuXi PharmaTech, Dr. Hegde served as General Manager of Drug Delivery Research Lab at USV Ltd, one of the largest Indian generic pharmaceutical companies. In this position, Dr. Hegde oversaw the development and registration of formulations to be exported to the American and European markets. His undertakings at USV Ltd involved closely collaborating with the US-FDA on Abbreviated New Drug Applicant (ANDA) products and EMEA for the Product Dossiers for the European markets.

Prior to joining USV Ltd, Dr. Hegde worked in Sandoz (the generic arm of Novartis). At Sandoz, he implemented cutting-edge drug development technology transfers from Novartis development sites in India to Novartis commercial launch sites in Austria, Bangladesh, and South Africa.

Dr. Hegde’s formulation and commercial manufacturing acumen, coupled with his operation experience makes him a valuable strategic addition to WuXi PharmaTech’s rapidly growing Pharmaceutical Development Services (PDS) division. In his new role as Vice President of Formulation Development Services, Dr. Hegde will oversee the company’s growing portfolio of formulation based service offerings. Dr. Hegde will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

“I am excited to welcome Dr. Hegde to WuXi PharmaTech. His strong and diverse industrial and operational background will be a great asset to our growing PDS division,” commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

Dr. Hegde received his Bachelor of Pharmacy degree from the University of Mumbai (formerly the University of Bombay) before going on to receive a Master of Pharmacy in Pharmacognosy and Phytochemistry from Banaras Hindu University. He returned to University of Mumbai to earn a Ph.D. in Biopharmaceutics and Pharmacokinetics in 1996, and has most recently received a Master of Financial Management from Somaiya Institute of Management Studies and Research. Dr. Hegde is a lifetime member of the Indian Pharmaceutical Association.

About WuXi PharmaTech Co., Ltd.

Founded in 2000, Shanghai-based WuXi PharmaTech is China’s leading drug R&D service company. As a research-driven and customer-focused company, WuXi PharmaTech offers global pharmaceutical and biopharmaceutical companies a diverse, value-added, and fully integrated portfolio of outsourcing services ranging from discovery chemistry, and process chemistry to service biology, bioanalytical chemistry, and large scale GMP manufacturing. WuXi PharmaTech assists its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save our clients both time and money. Currently, our customer list consists of 9 of the top 10 pharmaceutical companies in the world. For more information, please visit: http://www.wuxipharmatech.com .

Source: WuXi PharmaTech Co., Ltd.
Related Stocks:
NYSE:WX
collection